Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23216063 | 1.00 | FKBP1A (0.32) | FKBP1AGAATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL23216357 | 0.85 | FKBP1A (0.34) | FKBP1AGAATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL23216356 | 0.85 | FKBP1A (0.34) | FKBP1AGAATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL29745658 | 0.82 | FKBP1A (0.37) | FKBP1AGAATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL23215659 | 0.82 | FKBP1A (0.37) | FKBP1AGAATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL23215654 | 0.82 | FKBP1A (0.37) | FKBP1AGAATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL23216831 | 0.78 | NPC1 (0.39) | NPC1ALOX12RAB9A | |
| SCHEMBL29745153 | 0.78 | NPC1 (0.39) | NPC1ALOX12RAB9A | |
| SCHEMBL23215391 | 0.73 | AKT1 (0.39) | NPC1ALOX12RAB9A | |
| SCHEMBL29745487 | 0.73 | AKT1 (0.39) | NPC1ALOX12RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | FKBP1A 2808/4885GAA 2669/4885TSHR 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.